Sodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard for treatment of type 2 diabetes (T2D) with the added benefit to protect the kidney by means beyond glucose lowering. We took a high-level approach to evaluate the effects of empagliflozin (EMPA, most commonly prescribed SGLT2i) on renal metabolism and function in a pre-diabetic model of metabolic syndrome. Male and female 12-week-old TallyHo (TH) mice, and their closest genetic lean strain (Swiss-Webster, SW) were treated with a high-milk-fat diet (HMFD) plus/minus EMPA (@ 0.01%) for 12-weeks. Kidney weights and glomerular filtration rate (TH only) were slightly increased by EMPA. Glomerular feature analysis by unsupervised clustering revealed sexually-dimorphic clustering, and one unique cluster relating to EMPA. Periodic acid Schiff (PAS) positive areas (glycogen) were slightly reduced by EMPA. Likewise, phasor-fluorescent life-time imaging (FLIM) of free-to-protein bound NADH in kidney cortex showed a marginally greater reliance on oxidative phosphorylation with EMPA. Overall, net sodium, glucose, and albumin were slightly increased by EMPA in urine. Sodium transporter/channel profiling showed EMPA reduced the sodium phosphate cotransporter, type 2 (NaPi-2), but slightly increased collecting duct-associated γ-ENaC supporting distally-shifted sodium reabsorption. Microalbuminuria may reflect reduced reabsorption (rather than increased filtration). Finally, EMPA led to large changes in urine exosomal microRNA profile. Network analysis revealed "cancer pathways" and "FOXO signaling" as the major regulated pathways. Overall, EMPA treatment to pre-diabetic mice with limited renal disease showed developing changes in renal metabolism, which may preclude and underlie protection afforded against kidney disease with developing T2D.